BioNTech SE BNTX -0.15% Get Free Report reported a narrower loss for the second quarter on Monday. The company posted a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, versus a loss of ...

Clear Street raised the firm’s price target on BioNTech (BNTX) to $185 from $181 and keeps a Buy rating on the shares after updating the firm’s model to a year-end 2026 valuation following the company ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Pfizer (NYSE:PFE) shares traded higher in the premarket on Tuesday after the New York-based pharma giant reported better-than ...

Pfizer stock jumped Tuesday after the S&P 500 pharma titan beat second-quarter expectations on the back of solid cost-cutting ...

Victoria is cementing its position as a global hub for biotechnology and life sciences, with BioNTech establishing a state-of ...

Why it matters: In addition to ongoing clinical trial progress for BNT327, BioNTech was active on the business development ...

As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Massachusetts, a spokesperson told Fierce. | As part ...